Back Back
ProCE Banner Activity

CE / CME

Preventing Hospital Readmissions in Heart Failure With Quality-Focused Learning: Initial Analysis

Text Module
Establish and implement an evidence-based plan to reduce hospital readmissions in patients with HF.

Physicians : maximum of 0.50 AMA PRA Category 1 {Credit}

Pharmacists : 0.50 contact {hour} ({0.05} CEUs)

Released: November 22, 2019

Expiration: January 23, 2021

No longer available for credit.
Begin Activity

Share

Faculty

Nisha Gilotra

Nisha Gilotra, MD

Assistant Professor of Medicine
Director, Heart Failure Bridge Clinic
Johns Hopkins School of Medicine
Baltimore, Maryland

Stuart D. Russell

Stuart D. Russell, MD

Professor of Medicine
Duke University School of Medicine
Regional Director of Heart Failure
Duke University Medical Center
Durham, North Carolina

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

This activity is supported by an independent educational grant from

Novartis Pharmaceuticals Corporation

Target Audience

This program is intended for cardiologists, emergency medicine physicians, internists, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with HF.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Define performance measures from NQF and CMS relevant for HF readmissions.
  • Identify patients with HF who are at greatest risk of health complications and hospitalizations.
  • Develop a coordinated multidisciplinary plan for interventions that have been shown to be effective in reducing 30-day hospital readmissions in patients with HF.
  • Identify data available in your clinical setting and metrics your clinical team will use to evaluate performance improvement in HF hospital readmissions.
  • Describe the process to implement interventions for performance improvement in reducing 30-day readmissions in patients with HF.
  • Evaluate the effectiveness of interventions implemented to reduce 30-day readmissions for patients with HF.

Faculty Disclosure

Primary Author

Nisha Gilotra, MD

Assistant Professor of Medicine
Director, Heart Failure Bridge Clinic
Johns Hopkins School of Medicine
Baltimore, Maryland

Dr. Gilotra discloses the following: Consultant: scPharmaceuticals Grants/Research Support: Intracellular Therapeutics

Stuart D. Russell, MD

Professor of Medicine
Duke University School of Medicine
Regional Director of Heart Failure
Duke University Medical Center
Durham, North Carolina

Dr. Russell has nothing to disclose.

Instructions for Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation:
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Grant Supporter: Novartis Pharmaceuticals Corporation

Pharmacist Accreditation Statement:
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-19-099-H01-P, 0.5 contact hours (0.05 CEU).

Additional Information

Program Medium

This program has been made available online.


Goal


The goal of the proposed curriculum is to provide cardiologists, pharmacists, nurse practitioners, and other clinicians guidance on establishing and implementing an evidence-based plan to reduce hospital readmissions in patients with HF.